Jason Drew Smith net worth and biography

Jason Smith Biography and Net Worth

General Counsel of UroGen Pharma

Jason Smith has been named General Counsel and Chief Compliance Officer. Mr. Smith comes to UroGen from Pfizer where he spent the last 11 years. Jason joined Pfizer as Chief Counsel, Vaccines, and was subsequently named legal lead for the North American Region of Pfizer Essential Health. Mr. Smith most recently served as Chief Counsel, Oncology, beginning in 2016. Mr. Smith worked at Wyeth, LLC from December 2001 until Pfizer’s acquisition of the company in October 2009. He started at Wyeth as antitrust counsel and moved into a Global Product Counsel position in 2005, supporting various brands in the primary care portfolio. In 2008, Mr. Smith was appointed Chief Counsel, U.S. Pharmaceuticals, leading a team of lawyers supporting the prescription pharmaceuticals businesses. Before joining Wyeth, Mr. Smith was an associate at Howrey, Simon, Arnold & White in Washington, DC, in the antitrust and commercial litigation groups. Prior to Howrey, Mr. Smith was a Law Clerk to the Honorable Robert E. Payne of the United States District Court for the Eastern District of Virginia, Richmond Division. He received his bachelor’s degree in Economics, cum laude, from Binghamton University and his Doctor of Jurisprudence degree, with high honors, from George Washington University.

What is Jason Drew Smith's net worth?: The estimated net worth of Jason Drew Smith is at least $282,278.94 as of September 9th, 2024. Mr. Smith owns 25,226 shares of UroGen Pharma stock worth more than $282,279 as of December 18th. This net worth evaluation does not reflect any other investments that Mr. Smith may own. Additionally, Mr. Smith receives an annual salary of $864,190.00 as General Counsel at UroGen Pharma. Learn More about Jason Drew Smith's net worth.
How old is Jason Drew Smith?: Mr. Smith is currently 52 years old. There are 4 older executives and no younger executives at UroGen Pharma. The oldest executive at UroGen Pharma is Dr. Mark P. Schoenberg M.D., Chief Medical Officer, who is 66 years old. Learn More on Jason Drew Smith's age.
What is Jason Drew Smith's salary?: As the General Counsel of UroGen Pharma Ltd., Mr. Smith earns $864,190.00 per year. The highest earning executive at UroGen Pharma is Ms. Elizabeth A. Barrett, President, CEO & Director, who commands a salary of $1,340,000.00 per year. Learn More on Jason Drew Smith's salary.
How do I contact Jason Drew Smith?: The corporate mailing address for Mr. Smith and other UroGen Pharma executives is 400 Alexander Park, Princeton NJ, 08540. UroGen Pharma can also be reached via phone at (646) 768-9780 and via email at [email protected]. Learn More on Jason Drew Smith's contact information.
Has Jason Drew Smith been buying or selling shares of UroGen Pharma?: Jason Drew Smith has not been actively trading shares of UroGen Pharma within the last three months. Most recently, Jason Drew Smith sold 1,521 shares of the business's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $13.08, for a transaction totalling $19,894.68. Following the completion of the sale, the general counsel now directly owns 25,226 shares of the company's stock, valued at $329,956.08. Learn More on Jason Drew Smith's trading history.
Who are UroGen Pharma's active insiders?: UroGen Pharma's insider roster includes Elizabeth Barrett (CEO), Molly Henderson (CFO), Mark Schoenberg (Insider), and Jason Smith (General Counsel). Learn More on UroGen Pharma's active insiders.
Are insiders buying or selling shares of UroGen Pharma?: In the last twelve months, insiders at the sold shares 6 times. They sold a total of 28,315 shares worth more than $405,360.32. The most recent insider tranaction occured on September, 9th when insider Mark Schoenberg sold 859 shares worth more than $11,235.72. Insiders at UroGen Pharma own 5.1% of the company. Learn More about insider trades at UroGen Pharma.
Information on this page was last updated on 9/9/2024.

Jason Drew Smith Insider Trading History at UroGen Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/9/2024	Sell	1,521	$13.08	$19,894.68	25,226
1/31/2024	Sell	4,993	$15.74	$78,589.82	18,824
8/31/2023	Sell	3,800	$18.01	$68,438.00	18,407
1/31/2023	Sell	1,636	$10.12	$16,556.32	12,600
1/31/2022	Sell	414	$7.58	$3,138.12
11/30/2021	Sell	3,803	$12.03	$45,750.09

Jason Drew Smith Buying and Selling Activity at UroGen Pharma

UroGen Pharma Company Overview

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Today's Range

Now: $11.19

$11.11

$11.49

50 Day Range

MA: $12.13

$11.04

$13.02

2 Week Range

Now: $11.19

$10.60

$20.70

Volume

150,087 shs

Average Volume

488,607 shs

Market Capitalization

$262.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06

This drone stock is setting up to transform medical supply delivery

From The Tomorrow Investor | Ad

Drone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.

Click here to see how a new partnership could catapult this drone suppliers' growth

Jason Smith Biography and Net Worth

What is Jason Drew Smith's net worth?

How old is Jason Drew Smith?

What is Jason Drew Smith's salary?

How do I contact Jason Drew Smith?

Has Jason Drew Smith been buying or selling shares of UroGen Pharma?

Who are UroGen Pharma's active insiders?

Are insiders buying or selling shares of UroGen Pharma?